Publications, Pharmaceutical

Developing in vitro dissolution tests for orally inhaled drug products

The fate of inhaled drug substances, in vivo, is not well-understood but is believed to be dependent, to some extent, on dissolution characteristics.

This paper presents work to develop an in vitro apparatus and standardized methodology for quantifying the dissolution behavior of orally inhaled drug products. The developed solution incorporates an aerosol dose collection apparatus that collects the dose over a large area, and a modified USP Apparatus V Paddle Over Disc for dissolution testing. The discriminating ability of this solution was demonstrated via testing with a range of commercially available orally inhaled drug products (MDIs and DPIs). Good correlation was observed between in vivo mean absorption time and in vitro dissolution half-life. It is concluded that the developed solution has potential for compendial and QC testing and in the development of both branded and generic orally inhaled drug products.

Download Publication
10 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Device Innovations

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
9 Jun 2022

Aptar Pharma discusses digital therapeutics for chronic conditions

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
1 5 6 7 8 9 19
Back To Top